Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568878 · ClinicalTrials.gov registry record · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
A Phase 3 study of Depression and Anxiety, sponsored by Montana State University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT02568878 is a Phase 3 study of Depression and Anxiety that is actively recruiting participants, run by Montana State University. The registered enrollment target is 29 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02568878, a Phase 3 study of Depression and Anxiety, is actively recruiting participants, sponsored by Montana State University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
Conditions Studied
Interventions
- DRUG Creatine monohydrate
Study Locations (1)
Montana
- Montana State University College of Nursing (Missoula campus) - Missoula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02568878
The ClinicalTrials.gov registry entry for NCT02568878 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The listed sponsor is Montana State University, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Creatine monohydrate is the first listed.
NCT02568878 reports 1 study location spanning 1 distinct geographic area - top geographies include Montana.
Frequently Asked Questions
What is clinical trial NCT02568878 about?
NCT02568878 is a clinical study titled "Creatine for Depressed Male and Female Methamphetamine Users". * Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
What is the current status of trial NCT02568878?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2015-11. Estimated completion is 2017-05.
What conditions does trial NCT02568878 study?
This clinical trial studies the following conditions: Depression, Anxiety, Methamphetamine-dependence.
What interventions are being tested in trial NCT02568878?
The interventions under investigation include: Creatine monohydrate (DRUG).
Who is sponsoring clinical trial NCT02568878?
This trial is sponsored by Montana State University, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02568878 being conducted?
This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.